Formulation teams preparing solid dosage forms for direct compression often face a familiar obstacle: a powder blend that looks promising on paper but fails to compress into a tablet with adequate hardness, or that disintegrates too slowly once swallowed. This compressibility and disintegration trade-off is one of the recurring technical hurdles pharmaceutical manufacturers encounter when selecting excipients, and it is prompting renewed attention to microcrystalline cellulose (MCC) as a core formulation component.
Direct compression is widely favored over wet granulation because it removes several processing steps, shortening production time and reducing equipment needs. The approach only works reliably, however, if the filler-binder in the blend can be compacted into a tablet that holds together during handling and coating, while still breaking apart quickly enough for the active ingredient to be released in the body. Formulators evaluating excipient options for 2026 production lines are weighing these two requirements against each other as they select between available MCC grades.
Shanghai Runkey Biotech Co., Ltd., a Shanghai-headquartered supplier of cellulose-based pharmaceutical, food, cosmetic and construction materials, positions its MCC line as a versatile binder and filler intended specifically for solid dosage manufacturing. According to the company, its MCC supports direct compression processes by providing binding strength that improves tablet hardness, paired with a disintegration function that allows tablets to break down for drug release. The combination is intended to let manufacturers reduce or bypass wet granulation while still meeting hardness and dissolution targets. Runkey offers multiple grades, including MCC 102, giving formulators a basis for comparing particle and compaction characteristics against the needs of a specific tablet formula.
The MCC line sits within a broader cellulose ether portfolio that the company manufactures to USP, BP and EP pharmacopoeia standards, a compliance scope that applies across its pharmaceutical-grade materials, including excipients such as hydroxypropyl methylcellulose used for film coating and controlled release. Runkey reports an annual production capacity exceeding 10,000 tons and says its products are exported to more than 50 countries, serving over 200 clients globally. The company holds ISO 9001 and ISO 14001 certifications and has maintained a visible presence at international pharmaceutical industry events such as CPHI China. Its technical development work is supported by research cooperation with academic partners, including Shenyang Pharmaceutical University, alongside a joint laboratory with Huazhong University of Science and Technology.
For manufacturers comparing excipients heading into 2026 production planning, the practical implication is that grade selection should be matched to the specific pressing behavior and disintegration profile required by a given tablet formula, rather than treating MCC as a single undifferentiated material. Pharmacopoeia compliance and consistent supply scale remain relevant considerations for manufacturers sourcing excipients across multiple markets. Runkey states that its materials are available through bulk supply arrangements supported by international shipping and supply chain management services.
About Shanghai Runkey Biotech Co., Ltd.
Shanghai Runkey Biotech Co., Ltd., operating under the Runkey brand, is a Shanghai-based supplier of high-purity cellulose ether products serving the pharmaceutical, construction, food, cosmetic and coatings industries. Established for more than ten years, the company reports a global business presence spanning Asia, Europe, North and South America, the Middle East, Africa and Australia. Runkey describes its mission as developing efficient, environmentally conscious cellulose solutions that address product stability and performance challenges across these sectors.
Media Contact Company Name: Shanghai Runkey Biotech Co., Ltd. Address: Pudong New Area, Shanghai, China Website: Shanghai Runkey Biotech official website
www.runkeycel.com
Shanghai Runkey Biotech Co., Ltd
